Skip to content
Disclosery

Checkpoint Capital L.P.

Follow

13F filer, CIK 1977548, SAN FRANCISCO, CA

Checkpoint Capital L.P. reported $214,592,996 across 8 holdings for the quarter ended 2025-06-30, in a 13F-HR filed 2025-08-14.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001977548-25-000006

Period
2025-06-30
Reported value
$215M
Holdings
8
Top 10 weight
100%
New
0
Sold out
6

Largest buys vs the previous quarter

SecurityShares changeApprox. value
CORTadded+338,917$24.9M
ARGXadded+34,977$19.3M
RYTMadded+152,760$9.65M
IRONadded+21,689$1.15M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
SLNOexited-172,902-$12.4M
PTGXreduced-93,873-$5.19M
STOKexited-730,717-$4.86M
RVMDreduced-112,011-$4.12M
TCRXexited-2,017,650-$2.78M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q2 2025

Share positions as resolved from 13F-HR 0001977548-25-000006, largest first. % of portfolio is the value over $214,592,996, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
ARGXARGENX SEQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 92,500 shares; 2024Q4: 92,500 shares; 2025Q1: 115,000 shares; 2025Q2: 149,977 shares 149,977$82.7M38.52%+34,977Timeline
RYTMRHYTHM PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 663,381 shares; 2024Q4: 727,982 shares; 2025Q1: 907,240 shares; 2025Q2: 1,060,000 shares 1,060,000$67M31.21%+152,760Timeline
CORTCORCEPT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 5,000 shares; 2025Q2: 343,917 shares 343,917$25.2M11.76%+338,917Timeline
IRONDISC MEDICINE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 25,543 shares; 2024Q4: 185,000 shares; 2025Q1: 243,311 shares; 2025Q2: 265,000 shares 265,000$14M6.54%+21,689Timeline
RVMDREVOLUTION MEDICINES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 210,000 shares; 2025Q1: 392,011 shares; 2025Q2: 280,000 shares 280,000$10.3M4.8%-112,011Timeline
SEPNSEPTERNA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 824,878 shares; 2025Q2: 586,473 shares 586,473$6.2M2.89%-238,405Timeline
KYMRKYMERA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 77,535 shares; 2025Q1: 136,605 shares; 2025Q2: 106,991 shares 106,991$4.67M2.18%-29,614Timeline
PTGXPROTAGONIST THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 240,000 shares; 2024Q4: not reported; 2025Q1: 175,184 shares; 2025Q2: 81,311 shares 81,311$4.49M2.09%-93,873Timeline

Sold out in Q2 2025

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
SLNOSOLENO THERAPEUTICS INC172,902$12.4Mshares
STOKSTOKE THERAPEUTICS INC730,717$4.86Mshares
TCRXTSCAN THERAPEUTICS INC2,017,650$2.78Mshares
CDTXCIDARA THERAPEUTICS INC104,380$2.25Mshares
IMCRIMMUNOCORE HLDGS PLC9,011$267Kshares
RAPT THERAPEUTICS INCRAPT THERAPEUTICS INC109,830$134Kshares

How Q2 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001977548-25-000006 base2025-08-14acceptance time not in the bulk data set